The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis.

[1]  A. Desmoulière,et al.  Perspective Article: Tissue repair, contraction, and the myofibroblast , 2005, Wound Repair and Regeneration.

[2]  Chuanlong Zhu,et al.  Inhibitory Effect of Antisense Oligonucleotide Targeting TIMP-2 on Immune-Induced Liver Fibrosis , 2010, Digestive Diseases and Sciences.

[3]  A. Menderes,et al.  Matrix metalloproteinase‐2 and ‐9 activities in human keloids, hypertrophic and atrophic scars: a pilot study , 2009, Cell biochemistry and function.

[4]  R. Lafayette,et al.  Imatinib in the treatment of nephrogenic systemic fibrosis. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  T. Gambichler,et al.  Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. , 2008, Archives of dermatology.

[6]  A. Leask.  Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. , 2008, Cellular signalling.

[7]  B. Kelly,et al.  Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. , 2008, Journal of the American Academy of Dermatology.

[8]  S. Cowper,et al.  Clinical and histological findings in nephrogenic systemic fibrosis. , 2008, European journal of radiology.

[9]  M. Edward,et al.  Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis , 2008, The Journal of pathology.

[10]  A. Oto,et al.  Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. , 2008, AJR. American journal of roentgenology.

[11]  M. Plotkin,et al.  Pod1 induces myofibroblast differentiation in mesenchymal progenitor cells from mouse kidney , 2008, Journal of cellular biochemistry.

[12]  S. Morris,et al.  Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Three case reports and review of literature , 2008, Journal of clinical apheresis.

[13]  M. Burdick,et al.  Differentiation of Human Circulating Fibrocytes as Mediated by Transforming Growth Factor-β and Peroxisome Proliferator-activated Receptor γ* , 2007, Journal of Biological Chemistry.

[14]  I. Ono,et al.  Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of α‐smooth muscle actin, leading to reduction of wound contraction , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[15]  B. Hinz.  Formation and function of the myofibroblast during tissue repair. , 2007, The Journal of investigative dermatology.

[16]  J. Zic,et al.  Gadolinium deposition in nephrogenic fibrosing dermopathy. , 2007, Journal of the American Academy of Dermatology.

[17]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[18]  S. Shimazaki,et al.  Bone marrow‐derived myofibroblasts recruited to the upper dermis appear beneath regenerating epidermis after deep dermal burn injury , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[19]  P. Merkel,et al.  Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. , 2006, Arthritis and rheumatism.

[20]  E. Hedley‐Whyte,et al.  Nephrogenic fibrosing dermopathy with involvement of the dura mater , 2006, Virchows Archiv.

[21]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  Ming-yue Li,et al.  HGF reduces advancing lung fibrosis in mice: a potential role for MMP‐dependent myofibroblast apoptosis , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[24]  S. Cross,et al.  Matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase‐2 and ‐9 and tissue inhibitor of metalloproteinase‐1 during human dermal wound healing , 2004, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[25]  Shawn Cowper,et al.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood. , 2004, The international journal of biochemistry & cell biology.

[26]  F. Martinez,et al.  Mechanisms of pulmonary fibrosis. , 2004, Annual review of medicine.

[27]  C. Murry,et al.  Myofibroblast and endothelial cell proliferation during murine myocardial infarct repair. , 2003, The American journal of pathology.

[28]  Y. Inagaki,et al.  Interferon-γ Interferes with Transforming Growth Factor-β Signaling through Direct Interaction of YB-1 with Smad3* , 2003, Journal of Biological Chemistry.

[29]  W. Ting,et al.  Nephrogenic fibrosing dermopathy with systemic involvement. , 2003, Archives of dermatology.

[30]  H. Lan.  Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells , 2003, Current opinion in nephrology and hypertension.

[31]  Toshiyuki Yamamoto,et al.  Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. , 2002, Clinical immunology.

[32]  D. Abraham,et al.  Transforming growth factor-&bgr; and connective tissue growth factor: key cytokines in scleroderma pathogenesis , 2001, Current opinion in rheumatology.

[33]  Y. Okada,et al.  Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[34]  J. Varga,et al.  Transforming Growth Factor-β Repression of Matrix Metalloproteinase-1 in Dermal Fibroblasts Involves Smad3* , 2001, The Journal of Biological Chemistry.

[35]  Xiao-Fan Wang,et al.  The Loss of Smad3 Results in a Lower Rate of Bone Formation and Osteopenia Through Dysregulation of Osteoblast Differentiation and Apoptosis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  M. Goumans,et al.  Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice , 2001, The EMBO journal.

[37]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[38]  A. Roberts,et al.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β , 1999, The EMBO journal.

[39]  S. J. Chen,et al.  Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. , 1999, The Journal of investigative dermatology.

[40]  S. Shapiro,et al.  Matrix metalloproteinase degradation of extracellular matrix: biological consequences. , 1998, Current opinion in cell biology.

[41]  Erwin P. Bottinger,et al.  Biology of TGF-β in knockout and transgenic mouse models , 1997 .

[42]  M. Fujimoto,et al.  Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. , 1995, Journal of the American Academy of Dermatology.

[43]  B. Chua,et al.  Myofibroblasts from Scleroderma Skin Synthesize Elevated Levels of Collagen and Tissue Inhibitor of Metalloproteinase (TIMP-1) with Two Forms of TIMP-1 (*) , 1995, The Journal of Biological Chemistry.

[44]  George Bou-Gharios,et al.  Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[45]  A. Kulkarni,et al.  Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. , 1993, The American journal of pathology.

[46]  J. Saurat,et al.  Smooth muscle differentiation in scleroderma fibroblastic cells. , 1990, The American journal of pathology.

[47]  J. Heath,et al.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. , 1987, The EMBO journal.